GSK presents H5N1 vaccine results

GlaxoSmithKline (GSK) has announced clinical trial data from two new studies, which show that GSK's candidate pre-pandemic split antigen H5N1 vaccine, formulated with GSK's proprietary adjuvant system, provides a substantial level of cross-immunity against a ‘drifted' (diverse) strain of H5N1.

GlaxoSmithKline (GSK) has announced clinical trial data from two new studies, which show that GSK's candidate pre-pandemic split antigen H5N1 vaccine, formulated with GSK's proprietary adjuvant system, provides a substantial level of cross-immunity against a ‘drifted' (diverse) strain of H5N1.

It is hoped that the immune response elicited with this vaccine could help prepare or ‘prime' the immune system to rapidly respond against variants of the H5N1 strain and therefore protect the vaccinated population in the event of an H5N1 human pandemic.

In the first study presented at the ‘IX International Symposium on Respiratory Viral Infections (ISRVI)', data demonstrated that GSK's proprietary adjuvanted candidate pre-pandemic vaccine, containing very low levels of the Vietnam H5N1 antigen, elicits a strong cross-immune neutralising antibody response in humans against the Indonesian strain of the virus. The neutralising antibody seroconversion factor at Day 42 was shown to be 25 times greater when the vaccine contained the adjuvant system compared with that observed in the control group immunised with a non-adjuvanted vaccine (77.1% vs. < 3%).

Jean Stéphenne, president, GlaxoSmithKline Biologicals, said: "I am extremely encouraged by the new trial data that has been reported today on GSK's candidate pre-pandemic influenza vaccine.

"The data confirm that our pre-pandemic influenza vaccine has the ability to recognise and kill an H5N1 strain that is different to the one contained in the vaccine. This means that proactive administration of our pre-pandemic vaccine before or just after the start of the pandemic could help to substantially slow down the spread of disease."

GSK's proprietary adjuvant system also displays antigen-sparing properties. This could mean that by adding GSK's proprietary adjuvant system, vaccine manufacturing capacity could be increased more than tenfold.

The vaccine was shown to have an acceptable safety profile when compared to the control group.

Related:
Join the Discussion

Disclaimer:The view expressed here by our readers are not necessarily shared by Arabian Business, its employees, sponsors or its advertisers.

NOTE: Comments posted on arabianbusiness.com may be printed in the magazine Arabian Business

Please post responsibly. Commenter Rules

  • No comments yet, be the first!

All comments are subject to approval before appearing

Further reading

Features & Analysis
GCC's healthcare prognosis is looking good

GCC's healthcare prognosis is looking good

If there is one sector in the GCC with a robust prognosis it...

Is this the right prescription for Saudi Arabia?

Is this the right prescription for Saudi Arabia?

Saudi Arabia is expanding its healthcare industry on the back...

Revealed: Diagnosis for keeping the Gulf healthy

Revealed: Diagnosis for keeping the Gulf healthy

Gulf states have largely footed the bill for healthcare for decades...

Most Discussed
sponsoredTracking